Biotechnology company Full Circles Therapeutics announced on Thursday a significant study in Nature Biotechnology introducing a method for non-viral immune cell engineering using circular single-stranded DNA (cssDNA).

This approach addresses safety, efficacy and scalability concerns tied to traditional viral vector-based gene editing. The cssDNA method enables stable genomic integration, reducing risks and costs while enhancing the potential of cellular therapies for diseases such as cancer and autoimmune disorders.

A foundational patent for this technology has been granted in Japan, a key market for oncology and autoimmune treatments. The patent covers the use of generic cssDNA for targeted genome integration, demonstrating promising results in preclinical studies. This innovation supports the development of adaptable, nuclease editor-agnostic non-viral therapies with broad potential applications.